Helps compare the economic reality of different dose levels and different medications
There is a company currently called Agentix that is investigating a new CB1 receptor antagonist as an antiobesity drug and, very unfortunately, its OTC and only has a market cap of 3 million or else this entire article would be about why everyone should short it
The makers of blockbuster GLP-1 drugs, Novo and Lilly, have long complained the U.S
When you first insert the needle into the vial, there is often a small air gap at the tip of the needle
Bringing the price down really is going to impact those people who either dont have insurance for [GLP-1s] and have been paying out of pocket, or alternatively, those people who have chosen to go the route of purchasing them as compounded versions, says Cristy Gallagher, with the STOP Obesity Alliance at George Washington Universitys Milken Institute School of Public Health